Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 1015550 single rising dose in healthy Japanese males
NCT03542344Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2018
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of nerandomilast (3 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Number of Participants With Drug-related Adverse Events at 9 days. Started Jun 2018; status: completed.
02
Drugs
nerandomilast
Beyond the preview
Go deeper on NCT03542344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03542344.